![]() |
|
|
Vol. 289, Issue 3, 1301-1305, June 1999
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan (M.T., T.S., M.T., S.H.C., Y.K., H.E.); and Department of Toxicology, Kyoritsu College of Pharmacy, Minato-ku, Tokyo, Japan (M.K.)
| |
Abstract |
|---|
|
|
|---|
In the present study, we investigated the transport of ochratoxin A (OTA) by kidney-specific organic anion transporter 1 (OAT1). When expressed in Xenopus laevis oocytes, OAT1 mediated sodium-independent uptake of OTA (Km = 2.1 µM). Piroxicam, which has been shown to prevent the nephrotoxicity of OTA, inhibited OAT1-mediated uptake of OTA. By contrast, another protective compound, aspartame, did not. Using a cell line derived from the mouse kidney terminal proximal tubule (S3) transfected with OAT1 cDNA, we investigated the transport of OTA and also its effect on cell proliferation and cell viability. S3 cells expressing OAT1 mediated the saturable transport of OTA (Km = 0.57 µM). Cell proliferation was suppressed in S3 cells expressing OAT1 when exposed to 2 and 10 µM OTA. This suppression was rescued by the coaddition of 1 mM p-aminohippurate in the media. The present study indicates that OTA is transported by OAT1 and that the accumulation of OTA via OAT1 in proximal tubular cells is the primary event in the development of OTA nephrotoxicity.
| |
Introduction |
|---|
|
|
|---|
Ochratoxin
A (OTA) is a secondary fungal metabolite produced by Aspergillus
ohraceus and Penicillium verrucosum. Contamination of
foods, especially cereals, with OTA has been noted in East and Central
Europe, North Africa, North America, and Japan. In these countries, OTA
was detected in the blood of human and animals. Studies being conducted
for identification of the etiological factor of an endemic nephropathy
(Balkan Nephropathy) have implicated OTA in the development of this
disease (Kuiper-Goodman and Scott, 1989
; Breitholtz et al., 1991
;
Maaroufi et al., 1995
).
Within the body, OTA accumulates in several tissues, especially in the
kidney and liver, and is excreted mainly from the kidney (Kuiper-Goodman and Scott, 1989
). An in vivo study revealed that probenecid (a typical inhibitor of the renal organic anion transporter) decreased the renal clearance of OTA (Stein et al., 1985
). Using rabbit
renal basolateral membrane vesicles or rabbit renal tubular suspensions, it has been shown that the renal organic anion transport system mediates the uptake of OTA and may play a role in OTA toxicity (Sokol et al., 1988
; Groves et al., 1998
). Because more than 99% of
OTA is bound to plasma proteins (Chu, 1971
; Hagelberg et al., 1989
),
glomerular filtration of OTA is considered to be minimal. Thus, the
excretion of OTA into urine is thought to be mainly by tubular
secretion, presumably via the organic anion transport system (Gekle and
Silbernagl, 1994
).
Recently, a rat renal organic anion transporter (OAT1) was isolated
(Sekine et al., 1997
; Sweet et al., 1997
). OAT1 is expressed predominantly in the kidney and is localized on the basolateral membrane of the middle proximal tubule (S2) (Tojo et al., 1999
). As
OAT1 mediates the transport of various endogenous and exogenous organic
anions, including p-aminohippurate (PAH), it is considered the classical organic anion transporter responsible for the basolateral uptake of organic anions in renal epithelial cells.
In the present study, we investigated the transport of ochratoxin A by OAT1 using both Xenopus laevis oocytes for transient expression and culture cells for stable expression. Using the culture cells expressing OAT1, we also investigated the effect of ochratoxin A on cell proliferation and cell viability.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
[3H]OTA (547.6 GBq/mmol)
was purchased from Moravek Biochemicals Inc. (Brea, CA). Unlabeled OTA
was obtained by purification (Jung and Endou, 1989
). All other
chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).
cRNA Synthesis and Its Injection to X. laevis
Oocytes.
Capped cRNA for OAT1 and rat
Na+-dicarboxylate cotransporter (rNaDC1) was
synthesized in vitro using T7 RNA polymerase as described elsewhere
(Sekine et al., 1997
, 1998
). Defolliculated oocytes were injected with
15 ng of cRNA. For coexpression experiments, both OAT1 cRNA (12 ng) and
rNaDC1 cRNA (3 ng) were injected into the oocytes. After injection, the
oocytes were maintained in modified Barth's solution containing
gentamicin [88 mM NaCl, 1 mM KCl, 0.33 mM
Ca(NO3)2, 0.4 mM
CaCl2, 0.8 mM MgSO4, 2.4 mM
NaHCO3, 10 mM HEPES, and 50 µg/ml gentamicin,
pH 7.4, sterilized by filtration] for 3 days at 18°C.
Uptake Experiments in Oocytes. Three days after the injection of OAT1 and/or NaDC1 cRNA, uptake experiments were performed in ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, pH 7.4) containing radiolabeled substrates as indicated in each experiment. The uptake was stopped by the addition of ice-cold ND96 solution, and the oocytes were washed five times with the same solution. Single oocytes were dissolved in 0.25 ml of 10% sodium dodecyl sulfate and 2.5 ml of aquasol-2 (Packard, Meriden, CT), and radioactivity was determined.
Cell Culture.
S3 cells, which were derived from the terminal
portion of the mouse kidney proximal straight tubule (S3) of transgenic
mice harboring the simian virus 40 large T antigen gene, have been established as described previously (Hosoyamada et al., 1996
). OAT1-expressing S3 cells were obtained by transfecting S3 cells with
OAT1 cDNA in the mammalian expression vector pcDNA3.1 by the
electroporation method. These cells were routinely grown in RITC 80-7 medium (Kyokuto Pharmaceutical Industrial Co., Tokyo, Japan) containing
5% fetal bovine serum, 10 µg/ml transferrin, 0.08 U/ml insulin, and
10 ng/ml recombinant epidermal growth factor in a humidified incubator
at 33°C and 5% CO2 (Takeda et al., 1996
). S3
cells transfected with pcDNA3.1 without OAT1 cDNA were used as control cells.
Uptake Experiment in Cells. The cells were seeded in 24-well tissue culture plates at a cell density of 0.5 × 105 cells/well. After cultivation for 3 days, the cells were washed three times with Dulbecco's PBS, containing 5.6 mM D-glucose, and then preincubated with the same solution for 30 min in a water bath at 37°C. The cells were then incubated in Dulbecco's PBS containing 5.6 mM D-glucose with [3H]OTA as indicated in each experiment. The uptake was stopped by the addition of ice-cold buffer, and the cells were washed three times with the same solution. The cells of each well was dissolved with 0.5 ml of 0.1 N sodium hydroxide and 2.5 ml of aquasol-2, and radioactivity was determined.
Proliferation of Cells. OAT1-expressing S3 cells and control cells were seeded in 48-well tissue culture plates at a cell density of 0.3 × 105 cells/well and cultured for 18 h. Then, the RITC 80-7 medium was exchanged with medium with or without OTA (2 or 10 µM) and/or 1 mM PAH and then cultured for an additional 24 or 48 h. The cells were counted in a standard hemocytometer.
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium Bromide (MTT) Assay. OAT1-expressing S3 cells and control cells were cultured in 48-well plates with or without OTA (2 or 10 µM) and/or PAH (1 mM) as described above. After 24 h, 50 µl of 0.5% MTT was added to the media, and the cells were further incubated for 4 h. After solubilizing the cells with isopropanol/HCl solution, optical density (at 570 nm with 630 nm as a reference) was measured. Each value was expressed as the percentage of control.
Statistics. Data are expressed as mean ± S.E.M. Statistical differences were determined using Student's unpaired t test. Differences were considered significant at the level of p < .05.
| |
Results |
|---|
|
|
|---|
Uptake of OTA via OAT1 in X. laevis Oocytes.
Figure 1 shows the uptake of 4 µM
[3H]OTA in X. laevis oocytes
expressing OAT1. Compared with control oocytes (noninjected oocytes),
oocytes injected with OAT1 cRNA showed significantly higher uptake of
[3H]OTA. The OAT1-mediated uptake increased
linearly up to 3 h.
|
), 1.82 ± 0.34 pmol/oocyte/h;
preincubation (+), 2.53 ± 0.37 pmol/oocyte/h). This result means
that the glutarate preloaded by rNaDC1 trans-stimulates the
uptake of OTA.
|
|
|
Uptake of OTA in OAT1-Expressing S3 Cells.
OTA transport was
examined also using culture cells stably expressing OAT1. OAT1 cDNA
subcloned into pcDNA3.1 was transfected into a cell line (S3) derived
from the proximal tubule of transgenic mice harboring the simian virus
40 large T antigen gene. Significant uptake of
[3H]OTA in OAT1-expressing S3 cells was
observed, and the specific uptake of [3H]OTA in
OAT1-expressing S3 cells increased linearly up to 2 min (Fig.
5A). As shown in Fig. 5B, we studied the
kinetics of OAT1-mediated [3H]OTA uptake.
Km and
Vmax values were determined to be
0.57 ± 0.06 µM and 6.4 ± 0.2 pmol/mg protein/min,
respectively (n = 3).
|
Effect of OTA on Cell Proliferation and Viability of
OAT1-Expressing S3 Cells.
We examined the effect of OTA on cell
proliferation and cell viability. When OAT1-expressing S3 cells were
cultured with 2 and 10 µM OTA in RITC 80 to 7 medium, proliferation
of the cells was significantly suppressed (Fig.
6B). This inhibitory effect of OTA on
cell proliferation was rescued by the coaddition of 1 mM PAH. In
contrast, in S3 cells, transfected with the pcDNA3.1 vector only, no
suppression of cell proliferation was observed following the addition
of 10 µM OTA (Fig. 6A). In the experiment shown in Fig.
7, we examined the cell viability by MTT
assay. After being exposed to 10 µM ochratoxin A for 24 h, the
viability of OAT1-expressing S3 cells decreased significantly, and this decrease was recovered by the simultaneous addition of 1 mM PAH in the
media. In this assay, the viability of the control cells was not
influenced by OTA.
|
|
| |
Discussion |
|---|
|
|
|---|
Chronic tubulointerstitial nephropathy (Balkan Nephropathy) is
developed in European countries, particularly Balkan countries (Castegnaro and Chernozemsky, 1987
; Kuiper-Goodman and Scott, 1989
). In
this endemic nephropathy, various tubular dysfunctions, such as tubular
proteinuria, and benign or malignant epidermal tumors are observed.
Etiologic studies have indicated that this endemic nephropathy is
caused by some environmental factor. Although the studies are not
conclusive, ochratoxin A is considered to be one of the causative
agents. Studies on the secretion and reabsorption of OTA in the renal
proximal tubules have suggested that OTA is a substrate of the renal
organic anion transport system (Sokol et al., 1988
; Groves et al.,
1998
).
The present study demonstrated that a renal multispecific organic anion
transporter (OAT1) mediates the high-affinity transport of OTA.
Transport of OTA by OAT1 was sodium-independent and
trans-stimulated by dicarboxylate preloading. The
Km values of OTA transport via OAT1
were determined to be 2.1 µM and 0.57 µM using the oocyte expression system and S3 cells stably expressing OAT1, respectively. These values are identical with that reported in an experiment using
renal proximal tubular cells (Groves et al., 1998
), where the
Km value of OTA was determined to be
1.4 µM. In S3 cells expressing OAT1, the addition of 2 and 10 µM
OTA resulted in significant suppression of cell proliferation. Cell
viability determined by MTT assay also decreased when the
cell-expressing OAT1 was exposed to OTA. This suppression of cell
growth and viability was rescued by the coaddition of PAH, a
high-affinity substrate of OAT1. The present cell system is not
equipped with the unidentified luminal exit transporter of organic
anions; therefore, it does not mimic the physiological condition of the
proximal tubule cells completely. Despite this limitation, we consider
that these results suggest that the OTA accumulating in the proximal
tubular cells via OAT1 causes tubular dysfunction, possibly also in
Balkan Nephropathy.
It has been reported that several substrates such as piroxicam,
octanoate, and aspartame prevent the nephrotoxicity of OTA or inhibit
the transport of OTA (Baudrimont et al., 1995
; Creppy et al., 1995
;
Groves et al., 1998
). In this study, we demonstrated that piroxicam (a
nonsteroidal anti-inflammatory drug) and octanoate (a fatty acid)
inhibited OAT1-mediated uptake of OTA, like PAH and probenecid (a
typical inhibitor of OAT1). The inhibitory effect of piroxicam and
octanoate on OAT1-mediated OTA uptake can explain the prevention of OTA
nephrotoxicity by these compounds. Because these substrates, despite
their beneficial effects on the renal tubules, inhibit tubular
secretion of OTA, OTA will remain in the body for a longer period. In
contrast, aspartame (an artificial sweetener) showed no inhibition of
OAT1-mediated OTA uptake. Zingerle et al. (1997)
and Schwerdt et al.
(1997)
suggested that the reabsorption of OTA by renal proximal tubules
was, in part, mediated by a H+-coupled peptide
transporter. Aspartame (aspartyl-phenylalanine methyl ester) is a
dipeptide derivative and a candidate for substrate of a peptide
transporter of the proximal tubules. Thus, aspartame is considered to
prevent nephrotoxicity by reducing the rate of OTA reabsorption via
peptide transporter(s). Aspartame may be preferable to piroxicam or
octanoate, as it facilitates the urinary excretion of OTA without the
increased accumulation of OTA in the proximal tubule cells.
Citrinin is also a nephrotoxic mycotoxin, whose structure is related to
OTA. Citrinin has been shown to cause renal dysfunction, such as
glucosuria and proteinuria (Phillips et al., 1980
), and is considered
to be a substrate of the renal organic anion transporter (Berndt and
Hayes, 1982
; Berndt, 1983
). Because radiolabeled citrinin is
commercially unavailable, whether or not citrinin is a transportable substrate of OAT1 could not be determined. In this study, citrinin inhibited OAT1-mediated uptake of OTA. This result, along with previous
reports, demonstrates that OAT1 may transport citrinin and may also
play a crucial role in the development of citrinin nephrotoxicity.
Recently, it was reported that an organic anion-transporting
polypeptide-1 (oatp-1) mediated the transport of OTA (Kontaxi et al.,
1996
) and that oatp-1 is a member of a distinct organic anion
transporter family (oatp family). oatp-1 is localized at the
sinusoidal membrane of hepatocytes and the luminal membrane (S3) of
renal proximal tubular cells (Jacquemin et al., 1994
; Bergwerk et al.,
1996
). Therefore, it is believed that in the liver, oatp-1 mediates the
uptake of OTA from blood; in the kidney, oatp-1 reabsorbs OTA across
the luminal membrane. Thus, both OAT1 and oatp-1 transport OTA in the
proximal tubules. However, the Km
value of OTA uptake via oatp-1 in oocytes was 16.6 µM (Kontaxi et
al., 1996
), which is eight times higher than that via OAT1 (2.1 ± 0.3 µM in Fig. 3). In addition, because the main route of renal OTA
excretion is tubular secretion, the primary step in the accumulation of
OTA in renal proximal tubular cells is considered to be the basolateral
uptake of OTA from the blood. Considering these findings and the
inhibitory effects of piroxicam and octanoate, the OAT1 contribution
seems to be more important to the accumulation of OTA in proximal
tubules than that of oatp-1.
The toxicokinetics of OTA have been investigated in several animal
species (Hagelberg et al., 1989
; Galtier, 1991
). Although more than
99% of OTA was bound to plasma proteins in all species including
human, the plasma half-life of OTA is variable among species. It is
about six times longer in monkey (510 h) than in rat (58-120 h), and
the half-life of OTA in human is unknown but is believed to be similar
to that in monkey (Kuiper-Goodman and Scott, 1989
). It is possible that
transport rate of OTA via OAT1 is different among species, which causes
the different toxicokinetics. Excretion rate of OTA, however, is also
related to the reabsorption rate of OTA via
H+-peptide cotransporter and the efflux rate via
unidentified transporter at the luminal membrane. Further
investigations will help to elucidate the mechanisms underlying the
toxicokinetic differences of OTA. From the pathophysiological point of
view, it is very important to investigate the transport properties of
human OAT1 and other transporters responsible for the renal handling of
OTA.
In conclusion, we reported that a nephrotoxic mycotoxin, OTA, was transported by OAT1. Proximal tubular cells stably expressing OAT1 showed suppressed cell proliferation when cultured in media containing OTA. Another mycotoxin, citrinin, was capable of inhibition of OAT1-mediated uptake of OTA. The present study suggests that OAT1 plays a pivotal role in the development of nephrotoxicity of mycotoxins.
| |
Footnotes |
|---|
Accepted for publication February 4, 1999.
Received for publication November 3, 1998.
Send reprint requests to: Hitoshi Endou, M.D., Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan. E-mail: endouh{at}kyorin-u.ac.jp
| |
Abbreviations |
|---|
OAT, organic anion transporter; OTA, ochratoxin A; PAH, p-aminohippurate; rNaDC1, rat Na+-dicarboxylate cotransporter; oatp, organic anion transporting polypeptide; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
G. W. Schnabolk, G. L. Youngblood, and D. H. Sweet Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20) Am J Physiol Renal Physiol, August 1, 2006; 291(2): F314 - F321. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bakhiya, M. Stephani, A. Bahn, B. Ugele, A. Seidel, G. Burckhardt, and H. Glatt Uptake of Chemically Reactive, DNA-Damaging Sulfuric Acid Esters into Renal Cells by Human Organic Anion Transporters J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1414 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. J. Bow, J. L. Perry, J. D. Simon, and J. B. Pritchard The Impact of Plasma Protein Binding on the Renal Transport of Organic Anions J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 349 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Marin-Kuan, S. Nestler, C. Verguet, C. Bezencon, D. Piguet, R. Mansourian, J. Holzwarth, M. Grigorov, T. Delatour, P. Mantle, et al. A Toxicogenomics Approach to Identify New Plausible Epigenetic Mechanisms of Ochratoxin A Carcinogenicity in Rat Toxicol. Sci., January 1, 2006; 89(1): 120 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, C. E. Groves, A. Bahn, W. M. Barendt, M. D. Prado, M. Rodiger, V. Chatsudthipong, G. Burckhardt, and S. H. Wright Relative contribution of OAT and OCT transporters to organic electrolyte transport in rabbit proximal tubule Am J Physiol Renal Physiol, November 1, 2004; 287(5): F999 - F1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bahn, C. Ebbinghaus, D. Ebbinghaus, E. G. Ponimaskin, L. Fuzesi, G. Burckhardt, and Y. Hagos EXPRESSION STUDIES AND FUNCTIONAL CHARACTERIZATION OF RENAL HUMAN ORGANIC ANION TRANSPORTER 1 ISOFORMS Drug Metab. Dispos., April 1, 2004; 32(4): 424 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Eraly, K. T. Bush, R. V. Sampogna, V. Bhatnagar, and S. K. Nigam The Molecular Pharmacology of Organic Anion Transporters: from DNA to FDA? Mol. Pharmacol., March 1, 2004; 65(3): 479 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Gerk, J. A. Moscow, and P. J. McNamara BASOLATERAL ACTIVE UPTAKE OF NITROFURANTOIN IN THE CIT3 CELL CULTURE MODEL OF LACTATION Drug Metab. Dispos., June 1, 2003; 31(6): 691 - 693. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Enomoto, M. Takeda, A. Tojo, T. Sekine, S. H. Cha, S. Khamdang, F. Takayama, I. Aoyama, S. Nakamura, H. Endou, et al. Role of Organic Anion Transporters in the Tubular Transport of Indoxyl Sulfate and the Induction of its Nephrotoxicity J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1711 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O'Brien, A. H. Heussner, and D. R. Dietrich Species-, Sex-, and Cell Type-Specific Effects of Ochratoxin A and B Toxicol. Sci., October 1, 2001; 63(2): 256 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Morita, H. Kusuhara, T. Sekine, H. Endou, and Y. Sugiyama Functional Characterization of Rat Organic Anion Transporter 2 in LLC-PK1 Cells J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1179 - 1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Mulato, E. S. Ho, and T. Cihlar Nonsteroidal Anti-Inflammatory Drugs Efficiently Reduce the Transport and Cytotoxicity of Adefovir Mediated by the Human Renal Organic Anion Transporter 1 J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 10 - 15. [Abstract] [Full Text] |
||||
![]() |
S. Wada, M. Tsuda, T. Sekine, S. H. Cha, M. Kimura, Y. Kanai, and H. Endou Rat Multispecific Organic Anion Transporter 1 (rOAT1) Transports Zidovudine, Acyclovir, and Other Antiviral Nucleoside Analogs J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 844 - 849. [Abstract] [Full Text] |
||||
![]() |
R. A. M. H. Van Aubel, R. Masereeuw, and F. G. M. Russel Molecular pharmacology of renal organic anion transporters Am J Physiol Renal Physiol, August 1, 2000; 279(2): F216 - F232. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Cha, T. Sekine, H. Kusuhara, E. Yu, J. Y. Kim, D. K. Kim, Y. Sugiyama, Y. Kanai, and H. Endou Molecular Cloning and Characterization of Multispecific Organic Anion Transporter 4 Expressed in the Placenta J. Biol. Chem., February 11, 2000; 275(6): 4507 - 4512. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||